Our choice of BPD-MA, a potent photosensitiser, as a fluorescence contrast agent made PDT treatment a useful therapeutic tool to assess the treatment monitoring capability of the instrument, enabling us to treat and monitor response using the same molecule.
The possibility of using the same molecule, firstly conjugated with fluorophores, to "label" cancer cells during endoscopy and then conjugated with chemotherapeutic drugs to treat tumors by bladder instillation, has important implications for a personalized approach to bladder cancer.
We now appreciate that nature has used the same molecules for a multitude of purposes in both brain and body.
We used the same molecules and solvents for the characterization and biofunctionalization (see section above).
Pathogenic processes use the same molecules and mechanisms which operate under normal conditions.
All tests used the same molecule with the same parameters: a fatty acid amide hydrolase molecule that, once ported to the cubic grid, consisted of 29880 charges on 297 × 297 × 297 grid points.
Biochemical analysis of EGFR inhibition using the same small molecule inhibitors further supported our cellular results and demonstrated the importance of complimentary approaches when analyzing signal transduction pathways.
The number of markers that can be evaluated on an individual biological sample could be increased if it were possible to remove fluorescent probes from cells such that new markers could be labeled and detected using the same fluorescent reporting molecules.
In such a case, it can be helpful to setup a differently configured job using the same start and target molecules.
